
Annual report 2025
added 02-27-2026
Aldeyra Therapeutics Net Debt 2011-2026 | ALDX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Aldeyra Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -129 M | -214 M | -62.8 M | -29.7 M | -47.4 M | -18.7 M | -10.7 M | -13.4 M | -7.27 M | -1.99 M | -791 K | 1.95 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.95 M | -214 M | -44.5 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
455 M | $ 9.33 | 1.41 % | $ 603 M | ||
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.87 | -2.13 % | $ 6.4 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
-83 M | $ 22.38 | 0.81 % | $ 3.71 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Galapagos NV
GLPG
|
-1.29 B | $ 28.15 | 1.04 % | $ 2.69 B | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Grifols, S.A.
GRFS
|
5.36 B | $ 8.22 | 3.92 % | $ 6.83 B | ||
|
Harmony Biosciences Holdings
HRMY
|
-608 M | $ 30.95 | -0.34 % | $ 1.78 B | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
ImmuCell Corporation
ICCC
|
3.77 M | $ 8.43 | -0.12 % | $ 76.1 M | ||
|
InflaRx N.V.
IFRX
|
-32.3 M | $ 1.97 | -0.51 % | $ 152 M | ||
|
Incyte Corporation
INCY
|
-3.06 B | $ 98.55 | -0.55 % | $ 19.2 B | ||
|
InMed Pharmaceuticals
INM
|
-8.52 M | $ 0.71 | 1.27 % | $ 1.74 M | ||
|
Innoviva
INVA
|
-293 M | $ 22.97 | -0.35 % | $ 1.55 B | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 104.02 | 2.41 % | $ 27.2 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Jaguar Health
JAGX
|
116 K | $ 7.34 | -6.79 % | $ 17.1 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
KalVista Pharmaceuticals
KALV
|
-55.5 M | $ 26.68 | 0.02 % | $ 1.44 B | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Innate Pharma S.A.
IPHA
|
-120 M | $ 1.45 | -2.68 % | $ 235 M | ||
|
Kamada Ltd.
KMDA
|
-70.2 M | $ 8.16 | 0.68 % | $ 260 M | ||
|
Krystal Biotech
KRYS
|
-487 M | $ 260.24 | 0.11 % | $ 7.53 B | ||
|
Kazia Therapeutics Limited
KZIA
|
-5.43 M | $ 13.58 | 9.34 % | $ 1.8 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
-71 M | $ 220.06 | -2.13 % | $ 4.02 B | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 2.94 | -1.67 % | $ 4.84 M | ||
|
Liquidia Corporation
LQDA
|
-72.5 M | $ 38.41 | 0.67 % | $ 3.31 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.08 | 0.62 % | $ 436 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-3.05 M | - | 17.91 % | $ 11.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 23.15 | 3.49 % | $ 2.95 B |